Neurocrine Biosciences Soars 12.98% on Strong Q1 Earnings

Neurocrine Biosciences Inc (NASDAQ:NBIX) rose 12.98% in pre-market trading on May 6, 2025, driven by strong financial performance and positive outlook for its key products.

Neurocrine Biosciences reported a strong financial position with approximately $1.8 billion in cash, supporting future growth and investment. The company's CEO, Kyle Gano, highlighted record new patient starts for Ingrezza, a key product in its portfolio. This positive news contributed to the stock's surge after hours, with retail buzz soaring.

The company's Q1 earnings beat forecasts, with sales projections for Ingrezza remaining solid at $2.5 billion to $2.6 billion. This reaffirmation of guidance further boosted investor confidence in the company's growth prospects. Additionally, the consensus rating for Neurocrine Biosciences is "Moderate Buy" with an average target price of $160.90, indicating a positive outlook from analysts.

Neurocrine Biosciences' revenue is expected to grow by 10% with the continued sales of Crenessity and Ingrezza, provided they can maintain the retail price. This growth projection, coupled with the company's strong financial position and positive earnings report, has positioned Neurocrine Biosciences for continued success in the market.